- Home
- DCM vs PLUR Comparison
DCM vs PLUR Comparison
Compare DCM & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCM | PLUR |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 12.5M |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | DCM | PLUR |
|---|---|---|
| Price | $3.80 | $1.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 14.2K |
| Earning Date | 01-30-2018 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,847,163.00 | $1,016,000.00 |
| Revenue This Year | N/A | $902.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | N/A | $0.85 |
| 52 Week High | N/A | $4.87 |
Technical Indicators
Market Signals| Indicator | DCM | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 56.08 |
| Support Level | N/A | $0.88 |
| Resistance Level | N/A | $1.85 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 0.00 | 55.35 |
Price Performance
Historical ComparisonAbout PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.